Related Experiment Video
Updated: Jan 11, 2026
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Long-Term Outcomes and Post-Ablation Medication De-Escalation After Catheter Ablation for Premature Ventricular
Chung-Yu Lin1,2,3, Chien-Wei Chuang1,2, Mingchih Chen1,2
1Graduate Institute of Business Administration, Fu Jen Catholic University, New Taipei City, Taiwan.
Insights
Radiofrequency catheter ablation effectively treats frequent premature ventricular complexes, reducing medication needs. Patients with heart failure require tailored management post-ablation for optimal outcomes.
Area of Science:
- Cardiology
- Electrophysiology
- Public Health
Background:
- Frequent premature ventricular complexes (PVCs) are linked to ventricular dysfunction and heart failure.
- Radiofrequency catheter ablation (RFCA) is a guideline-endorsed treatment for symptomatic or drug-refractory PVCs.
- Long-term real-world outcomes and medication de-escalation post-RFCA for PVCs require further characterization.
Purpose of the Study:
- To evaluate nationwide long-term outcomes of RFCA for frequent PVCs.
- To assess post-ablation antiarrhythmic drug utilization and de-escalation.
- To compare outcomes between patients with and without baseline heart failure.
Main Methods:
- Nationwide retrospective cohort study using Taiwan's National Health Insurance Research Database (2002-2018).
- Included adults undergoing first-time RFCA for PVCs, with follow-up to 2021.
- Assessed all-cause mortality, heart failure rehospitalization, and antiarrhythmic drug use (prevalence and dose).
Main Results:
- 4195 patients included; 7% had baseline heart failure.
- Baseline heart failure significantly predicted mortality and heart failure rehospitalization.
- RFCA reduced antiarrhythmic drug use from 58% to 31% at 1 year, with dose de-escalation observed.
- Patients with heart failure showed less reduction in beta-blockers and Class III agents.
Conclusions:
- RFCA offers real-world benefits for frequent PVCs, with distinct prognoses for heart failure patients.
- RFCA is associated with significant reductions in antiarrhythmic medication use, suggesting therapeutic and economic advantages.
- Findings support RFCA in long-term PVC management; prospective studies are needed for optimal patient selection and timing.
Purpose:
Frequent premature ventricular complexes are increasingly recognized as a contributor to ventricular dysfunction and progression to heart failure. Current clinical guidelines endorse radiofrequency catheter ablation as an effective treatment for symptomatic or drug-refractory premature ventricular complexes. However, nationwide long-term real-world outcomes, particularly those related to post-ablation medication de-escalation, remain insufficiently characterized.
Patients And Methods:
Using Taiwan's National Health Insurance Research Database, we conducted a nationwide retrospective cohort study of adults who underwent first-time radiofrequency catheter ablation for premature ventricular complexes between 2002 and 2018, with follow-up extending to December 31, 2021, allowing for up to three years of observation. Clinical outcomes included all-cause mortality and heart failure rehospitalization. Antiarrhythmic drug utilization was assessed through both prescription prevalence and defined daily dose, evaluated at baseline, 90 days, and 1 year post-ablation. Subgroup analyses were stratified by baseline heart failure status.
Results:
A total of 4195 patients (mean age 53±15 years; 49% women) were included, of whom 7% had heart failure. Baseline heart failure independently predicted mortality (hazard ratio 3.99, 95% confidence interval 2.71-5.88) and heart failure rehospitalization (hazard ratio 7.29, 95% confidence interval 5.49-9.66). Radiofrequency catheter ablation was associated with substantial reductions in antiarrhythmic drug use, declining from 58% before the procedure to 31% at 1 year. Medication analysis confirmed dose de-escalation, particularly for mexiletine, propafenone, and amiodarone. However, patients with heart failure exhibited smaller reductions in beta-blockers and Class III agents.
Conclusion:
This nationwide cohort offers real-world insight into radiofrequency catheter ablation outcomes for frequent premature ventricular complexes, highlighting divergent prognoses between patients with and without heart failure. Radiofrequency catheter ablation was associated with meaningful reductions in antiarrhythmic medication use, underscoring its potential therapeutic and economic benefits. These findings support radiofrequency catheter ablation as a component of long-term management strategies, while future prospective studies are needed to refine candidate selection and timing of intervention.
More Related Videos
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:25Dysrhythmias VI: Management of Dysrhythmias
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management